Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Chairman Stanley T. Crooke sold 11,000 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $55.35, for a total value of $608,850.00. Following the transaction, the chairman now owns 48,014 shares of the company’s stock, valued at $2,657,574.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Ionis Pharmaceuticals, Inc. (NASDAQ IONS) opened at 46.98 on Friday. Ionis Pharmaceuticals, Inc. has a 12-month low of $24.58 and a 12-month high of $60.01. The company has a market capitalization of $5.84 billion, a P/E ratio of 225.87 and a beta of 3.14. The company’s 50 day moving average price is $51.56 and its 200-day moving average price is $47.09.
Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings results on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.03. The firm had revenue of $104.15 million for the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The business’s revenue for the quarter was up 170.7% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.47) earnings per share. Equities analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.20) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Ionis Pharmaceuticals, Inc. (IONS) Chairman Sells $608,850.00 in Stock” was originally reported by BNB Daily and is the property of of BNB Daily. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.baseball-news-blog.com/2017/08/19/ionis-pharmaceuticals-inc-ions-chairman-sells-608850-00-in-stock-updated-updated-updated.html.
Institutional investors have recently modified their holdings of the company. Nomura Holdings Inc. increased its position in Ionis Pharmaceuticals by 105.7% in the first quarter. Nomura Holdings Inc. now owns 103,933 shares of the company’s stock worth $4,179,000 after buying an additional 53,395 shares in the last quarter. Wellington Management Group LLP increased its position in Ionis Pharmaceuticals by 56.1% in the first quarter. Wellington Management Group LLP now owns 9,360,553 shares of the company’s stock worth $376,295,000 after buying an additional 3,364,621 shares in the last quarter. Creative Planning increased its position in Ionis Pharmaceuticals by 5.7% in the first quarter. Creative Planning now owns 26,856 shares of the company’s stock worth $1,080,000 after buying an additional 1,442 shares in the last quarter. Credit Suisse AG increased its position in Ionis Pharmaceuticals by 79.2% in the first quarter. Credit Suisse AG now owns 385,145 shares of the company’s stock worth $15,483,000 after buying an additional 170,192 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in Ionis Pharmaceuticals by 19.0% in the first quarter. Pacer Advisors Inc. now owns 13,037 shares of the company’s stock worth $524,000 after buying an additional 2,085 shares in the last quarter. Institutional investors and hedge funds own 89.08% of the company’s stock.
A number of analysts have weighed in on the company. Laidlaw restated a “buy” rating and set a $65.00 target price on shares of Ionis Pharmaceuticals in a report on Monday, August 14th. Jefferies Group LLC restated an “underperform” rating and set a $18.00 target price (up previously from $17.00) on shares of Ionis Pharmaceuticals in a report on Thursday, August 10th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 target price on the stock in a report on Monday, July 31st. BMO Capital Markets upped their price target on Ionis Pharmaceuticals from $67.00 to $69.00 and gave the company an “outperform” rating in a research note on Monday, August 14th. Finally, Sanford C. Bernstein started coverage on Ionis Pharmaceuticals in a research note on Thursday, July 27th. They set a “market perform” rating and a $57.00 price target on the stock. Three analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company’s stock. Ionis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $48.91.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.